| Literature DB >> 29734330 |
Agnese Collino1, Alberto Termanini2, Paola Nicoli1, Giuseppe Diaferia1, Sara Polletti3, Camilla Recordati4, Vittoria Castiglioni4, Donatella Caruso5, Nico Mitro5, Gioacchino Natoli2,3, Serena Ghisletti2.
Abstract
Chronic inflammation promotes oncogenic transformation and tumor progression. Many inflammatory agents also generate a toxic microenvironment, implying that adaptive mechanisms must be deployed for cells to survive and undergo transformation in such unfavorable contexts. A paradigmatic case is represented by cancers occurring in pediatric patients with genetic defects of hepatocyte phosphatidylcholine transporters and in the corresponding mouse model (Mdr2-/- mice), in which impaired bile salt emulsification leads to chronic hepatocyte damage and inflammation, eventually resulting in oncogenic transformation. By combining genomics and metabolomics, we found that the transition from inflammation to cancer in Mdr2-/- mice was linked to the sustained transcriptional activation of metabolic detoxification systems and transporters by the Constitutive Androstane Receptor (CAR), a hepatocyte-specific nuclear receptor. Activation of CAR-dependent gene expression programs coincided with reduced content of toxic bile acids in cancer nodules relative to inflamed livers. Treatment of Mdr2-/- mice with a CAR inhibitor blocked cancer progression and caused a partial regression of existing tumors. These results indicate that the acquisition of resistance to endo- or xeno-biotic toxicity is critical for cancers that develop in toxic microenvironments.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29734330 PMCID: PMC5957449 DOI: 10.1371/journal.pgen.1007380
Source DB: PubMed Journal: PLoS Genet ISSN: 1553-7390 Impact factor: 5.917
Fig 1Transcriptional alterations accompanying Mdr2 liver disease progression.
(A) Volcano plots reporting differentially expressed genes (up-regulated brown, down-regulated green) identified by comparing WT and inflamed Mdr2 livers (left panel) and Mdr2 inflamed livers and tumors (right panel). The y-axis shows the -Log10 of the P-values determined by Cuffdiff analysis. (B) Gene ontology analyses on the sets of differentially expressed genes (up- and down-regulated) in each comparison. (C) Representative RNA-seq snapshots of differentially expressed genes. (D) Representative genes belonging to cell adhesion and ECM/cytoskeleton organization (Col4a5, Chd1, Mmp2), to glutathione metabolism (Gclc, Gstt2, Gstm1,) and to metabolism of xenobiotics by CYP450 enzymes (Cyp2c39, Cyp4a32, Nr1i3). Differences were assessed using two-sided Mann-Whitney test (p < 0.05).
Bile acids content in Mdr2 livers.
| average ng/mg of protein lysate | |||||
|---|---|---|---|---|---|
| -OH groups | Normal (n = 5) | Inflamed (n = 5) | HCC (n = 5) | ||
| 3 | tauromuricholic acid | 985.04 ± 371.07 | 3716.44 ± 858.25 | 2380.62 ± 414.59 | |
| 3 | muricholic acid omega | 1.22 ± 1.42 | 17.85 ± 9.29 | 4.39 ± 4.32 | |
| 3 | muricholic acid beta | 12.05 ± 9.9 | 150.78 ± 68.91 | 73.66 ± 33.75 | |
| 3 | muricholic acid alpha | 1.05 ± 0.99 | 6.12 ± 2.11 | 2.61 ± 1.64 | |
| 3 | glycocholic acid | 2.14 ± 1.05 | 3.79 ± 0.88 | 1.68 ± 0.44 | |
| 3 | taurocholic acid | 730.99 ± 265.15 | 1831.86 ± 380.33 | 1168.44 ± 122.87 | |
| 3 | cholic acid | 36.44 ± 17.69 | 32.93 ± 17.93 | 34.56 ± 25.39 | |
| 2 | tauroursodeoxycholic acid | 33.64 ± 11.97 | 93.52 ± 54.12 | 25.82 ± 15.57 | |
| 2 | ursodeoxycholic acid | 5.37 ± 1.3 | 5.36 ± 0.9 | 6.54 ± 4.07 | |
| 2 | taurochenodeoxycholic acid | 24.56 ± 10.69 | 110.93 ± 37.69 | 60.84 ± 23.92 | |
| 2 | hyodeoxycholic acid | 1.39 ± 0.78 | 1.32 ± 0.31 | 1.32 ± 0.62 | |
| 2 | chenodeoxycholic acid | 7.25 ± 6.04 | 0.63 ± 0.44 | 1.85 ± 0.59 | |
| 2 | deoxycholic acid | 3.54 ± 1.51 | 1.24 ± 0.53 | 3.2 ± 1.62 | |
| 1 | taurolithocholic acid | 6.44 ± 3.27 | 3.95 ± 0.92 | 4.41 ± 0.72 | |
| 1 | lithocholic acid | 23.28 ± 7.87 | 35.93 ± 9.12 | 17.6 ± 14.01 | |